COMP <GO>
CRSP vs CGON // PIOTROSKI F-SCORE QUALITY
CRISPR Therapeutics AG (NASDAQ) VS. CG Oncology Inc. (NASDAQ) • 15-METRIC TALLY: CRSP 2
— CGON 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: CGON
LAST: $49.99 (0.00%) • MKT CAP: $4.83B
piotroski-score
4/9
LAST: $64.06 (+3.39%) • MKT CAP: $5.49B
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. CGON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | CGON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | -20.80% | -9.80 | CGON | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | -2.35% | -4.24 | CGON | /fcf-yield <GO> |
| Operating Margin | -60.00% | -12.10% | -47.90 | CGON | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -10.20% | -49.80 | CGON | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 8.80% | -73.80 | CGON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.97 | 26.00 | -18.03 | CGON | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 5/9 | -1.00 | CGON | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.0 | 41.5 | +2.50 | CRSP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.07 | +0.05 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 20.0x | +8.00 | CGON | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.83B | $5.49B | -$658.5M | CGON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | CGON REV | CRSP GROSS % | CGON GROSS % | CRSP FCF | CGON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $534.2M | — | — | -$345.9M | -$132.5M |
| FY 2024 | $37.3M | $321.1M | — | — | -$144.7M | -$78.9M |
| FY 2023 | $371.2M | $155.3M | — | — | -$277.1M | -$45.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
CGON // BETA 1.07